Investor News    (for clinical news, click here)

Spectros Closes Agreement With Caliper Life Sciences
(June 2008)

Spectros closed a technology agreement with Caliper Life Sciences (NASDAQ:CALP) for undisclosed terms. Under this agreement, Caliper will have access to certain optical technologies related to optical imaging in drug discovery and clinical life sciences. Caliper Life Sciences, Inc. engages in the sale of products, services, and integrated systems consisting of instruments, software, and reagents to life sciences biomedical and pharmaceutical researchers worldwide. Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer, and out-licenses technology to biotech concerns outside of our clinical product line. Spectros anticipates additional service, technology, or licensing to be closed with other life sciences concerns in the coming year.

Spectros Contrast-Guided Intervention Patent Allowed in Japan
(May 2008)

This month, the Japanese patent office indicated that they will allow patents on Spectros' Contrast Guided Identification to issue broad protection for optical contrast guideance in Japan. This will expand Spectros intellectual property in areas as diverse as the surgical biopsy and treatment of cancer using optical contrast agents. A number of patents in tissue analysis and molecular imaging are pending in Europe and Japan, after issuance or license to Spectros in the United States.

Spectros Tissue Identification Patent Issues in Europe
(March 2008)

Spectros has broad, early, worldwide, and dominant intellectual property in 4 areas: tissue identification (identifying tissue by type, including by composition or identifying cancer), tissue analysis (measuring the tissue concentration of fat, water, hemoglobin, bilirubin, or even drugs), molecular imaging (imaging disease and disease processes such as cancer), implantable nanotechnology (such as congestive heart failure monitoring). Supporting this are key algorithms such as Ischemia Detection, Pulse and Continuous Spectroscopy Analysis in Tissue, and hardware such as low-thermal-transfer broadband light sources and optical-electrical hybrid connectors with memory. This month, the European patent office extended coverage on Spectros' Tissue Identification to issue broad protection for tissue identification in Europe, including Germany, France, Great Brittain, and the Netherlands. This will solidify Spectros intellectual property in areas as diverse as the optical detection of cancer and embedded surgical guidance. A number of patents in tissue analysis and molecular imaging are pending in Europe and Japan, after issuance or license to Spectros in the United States.

Spectros Will Pursue Out-Licensing Program
(February 2008)

Spectros has significant intellectual property in optical life-science technology. Spectros will now develop a licensing program to offer the advantages of Spectros technology to biotech concerns outside of the Spectros primary clinical product line. Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer, and out-licenses technology to biotech concerns outside of our clinical product line. Our lead product, T-Stat®, is FDA approved and marketed in the U.S. and Europe for detection of ischemia, an insufficient blood flow to tissue. In 2009, we anticipate marketing approval for a spectroscopic breast cancer screening device.

2007 Revenue up 36%
(January 2008)

Spectros 2007 year-over-year sales rose 36%, reflecting growing acceptance of Ischemia monitoring in a broadening array of applications and clinical research areas. "We are pleased that hospitals are now recognizing the benefits of Ischemia Detection in their practices. As predicted by Red Herring, the market for such products in molecular detection, molecular imaging, and treatment guidance, is expected to be over $10 billion annually. We expect significant growth for the next 3-5 years," notes David Benaron, CEO.

Spectros is currently the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system. With introduction of probes that monitor in the cranial region, Spectros will have the opportunity to compete with cerebral oximetry concerns such as Somanetics, CAS Medical, and others. Further, Devices for the real-time monitoring of surgery, vascular repair, and breast cancer are entering Phase III trials. (Disclaimer: Some of the applications noted above are for research use only, and have not yet been reviewed or approved by the FDA. Past performance is not guaranteed to be a predictor of future performance)

T-Stat® ix Measures Tissue Composition in Breast, Brain, Gut in Real Time
(December 2007)
T-Stat®-ix, which monitors, characterizes, and classifies tissue based upon metabolic profile and chemical make-up, has now been validated to monitor chemical composition such as blood content, metabolism index, fat content, tissue volume, as well as abnormal hemoglobins such as met-Hb, carboxy-Hb, bilirubin, and beta-carotene (a marker of fat). Clinical trials are nearing at several centers, including Stanford, the University of California, and the University of Pennsylvania. The ix stands for "index" and has been developed under the FirstScan label, a consortium of academic centers and Spectros, to provides real-time, noninvasive tissue component characterization in various disease states. An overlay of optical and ultrasound information is also under study. This application is currently for research use only, and has not yet been reviewed or approved by the FDA.

Spectros cornerstone Tissue Identification patent allowed in Europe
(October 2007)
Spectros has broad, early, worldwide, and dominant intellectual property in 4 areas: tissue identification (identifying tissue by type, including by composition or identifying cancer), tissue analysis (measuring the tissue concentration of fat, water, hemoglobin, bilirubin, or even drugs), molecular imaging (imaging disease and disease processes such as cancer), implantable nanotechnology (such as congestive heart failure monitoring). This month, the European patent office agreed to issue broad protection for tissue identification in Europe. This will solidify Spectros intellectual property in areas as diverse as the optical detection of cancer and embedded surgical guidance. A number of patents in tissue analysis and molecular imaging are pending in Europe and Japan, after issuance or license to Spectros in the United States.

Neonatal ICUs Adopt T-Stat Platform
(September 2007)
T-Stat now provides real-time, noninvasive feedback to Neonatal ICUs, allowing physicians and nurses to receive rapid, quantitative feedback on the perfusion of their patients during supportive critical care. In turn, this has allowed for better management of volume, drips, and ventilator changes in these small and fragile patients. Multiple clinical centers are testing and adopting T-Stat as a new standard of care for their most fragile patients. T-Stat® probes now can monitor at somatic sites, as well as cranial sites for patients in whom the perfusion of the brain at risk, including monitoring of tissues in either or both of the internal and external carotid distributions.

T-Stat-ix for Breast Cancer Reaches Limited Production
(August 2007)
T-Stat-ix, which monitors, characterizes, and classifies tissue based upon metabolic profile and chemical make-up, has reached limited production, in anticipation of clinical trials at Stanford, the University of California, and the University of Pennsylvania. The ix stands for "index" and has been developed under the FirstScan label, a consortium of academic centers and Spectros, to provides real-time, noninvasive tissue component characterization in various disease states. First to trial will be testing in Breast Cancer screening, anticipated to begin clinical trials in 2008.

Israel Beinglass, former CTO Applied Materials, Joins Board of Directors
(July 2007)
Dr. Israel Beinglass, former CTO of Applied Materials (Nasdaq:AMAT), has joined the Board of Directors at Spectros Corporation. Before joining Applied Materials, Dr. Beinglass worked at Intel Corporation and IMP. While working at Intel he was the co-inventor of the Selective Tungsten Deposition. Dr. Beinglass has a Ph.D degree from the Hebrew University of Jerusalem in materials science and holds 27 US patents.

Cerebral/Cranial Probes Introduced
(June 2007)
Responding to clinical requests for cerebral monitoring, Spectros has broadened use of the T-Stat® sensors to operate within the domain of internal carotid blood supply. This allows T-Stat® to begin to compete with other cranial monitoring systems, such as NIRS and EEG spectral monitoring. By expanding the choices clinicians have in physiology monitoring, Spectros will play a growing role in ICU, ER, cancer, and cardiac monitoring.

Spectros Profiled in Red Herring Market Analysis
(May 2007)
Spectros, the world-leader in real-time noninvasive molecular detection, was profiled in a market report on optical detection devices. Red Herring noted that the "market for clinical ... [devices], as 'living tissue' monitors, extends beyond the wide range of conventional hospital and surgery settings to encompass emergency transport, pharmacy sales for at-home use, veterinary care, military field care, laboratory research, athletic performance training and biometric pass coding. Clinical ... devices have the potential to change the way medicine is done by combining an early warning system and extreme sensitivity to critical changes in physiological status. As an emerging technology on the cusp of a major breakthrough, ... [optical devices] are poised to become a dominant player the medical device and single-use disposables market place; [with] ... the potential for $2-3 billion in device sales and $12 billion annually in consumables sales."

Spectros Introduces Next-Generation T-Stat®
(May 2007)
Spectros introduces the next-generation T-Stat®, available in the Summer of 2007. This new device is capable of tracking multiple sites simultaneous, as well as performing new, advanced, real-time calculations that will assist icu and surgery users interpret ischemia data more readily. This new device will assist in the expansion of T-Stat® into new areas of use, including general surgery, vascular repair, trauma, and breast cancer.

Spectros Sales Rise 38% in 2006
(February 2007)
Spectros 2006 year-over-year sales rose 38%, reflecting growing acceptance of Tissue Oximetry in a broadening array of applications, and clinical studies showing outcome improvements. "We are pleased that physicians are now increasingly recognizing the compelling benefits of Ischemia Detection in their practices, and expect sales in Tissue Oximetry to grow considerably for the foreseeable future," comments David Benaron, CEO. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system. Devices for the real-time monitoring of surgery, vascular repair, and breast cancer are entering Phase III trials.

Spectros Commits to Ischemia-Directed Trial in Breast Cancer
(September 2006)
Spectros has made a seven-digit commitment to the Phase III trial for a large-scale pivotal trial of the detection of abnormal metabolism detection in patients at risk for breast disease, including breast cancer. The Spectros 303xi device has been tested in pilot FDA-directed trials in the colon, skin, and breast, and found to be sensitive to regional changes in cellular metabolism. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system.

Spectros Expands Market with T-Stat® Noninvasive Sto2 Soon Available for Neonates
(August 2006)
T-Stat® Sto2, which has been demonstrated sensitive to the presence of ischemia in tissues, will soon be available for neonatal use, with probes specifically designed for rapid application in small patients available mid-2007. This is ideal for ill patients who do not tolerate large, invasive, or indwelling sample lines. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system.

Spectros Expands Market with T-Stat® Effective in Reducing Colon Anastomosis Leak Due to Ischemia.
(May 2006)
T-Stat® was shown effective at reducing post-anastomotic leak in G.I. surgery, effectively detecting 75% of the patients who would go on to develop post-operative leak. The T-Stat Ischemia Detection System is approved for use during procedures in which a patient it at-risk for local ischemia. Spectros is the leader in real-time noninvasive somatic molecular monitoring, such as the T-Stat® 303 ischemia detection system.

Clinical News